Topical antimicrobials in burn wounds
Key Points
- Silver sulfadiazine remains the first-line topical agent for most burn wounds due to its broad-spectrum activity, low cost, and ease of application [4, 5].
- Mafenide acetate cream is the preferred agent when eschar penetration is needed, particularly for ears and cartilaginous structures, but limit duration and area of application to avoid metabolic acidosis [4].
- For MRSA-colonized wounds, mupirocin is highly effective topically and should be considered as a targeted treatment based on wound culture results [7].
- Topical agents retain activity against most MDROs, but resistance patterns should be monitored locally; mafenide acetate, silver nitrate, and Dakin's solution show the broadest MDRO coverage [6].
- Match topical agent selection to wound phase: optimize re-epithelialization in superficial burns, prioritize antimicrobial suppression in deep burns awaiting excision [5].
- For angioinvasive fungal wound infections, topical nystatin powder at high concentration may be effective when systemic antifungals have failed [9].
Overview
Topical antimicrobial therapy is one of the most fundamental decisions in burn wound management. Burn wounds lose their primary barrier to microbial invasion within hours of injury, creating a colonization-prone surface that can progress to invasive infection if not managed effectively. Selecting the right topical agent for the right wound at the right time directly affects infection rates, healing times, and patient comfort.
History and development
The foundation of modern topical burn wound therapy rests on the development of silver-based agents in the 1960s. Moyer et al. [1] introduced 0.5% silver nitrate solution for the treatment of large burns, establishing that topical silver could substantially reduce bacterial colonization and improve survival in major thermal injuries. Brentano et al. [2] subsequently documented the bacteriological effects of silver nitrate treatment, demonstrating reduced wound colonization in large burns. These landmark studies shifted burn care from systemic antibiotics alone toward a combined topical strategy.
Silver sulfadiazine (SSD) rapidly became the most widely used topical agent after Stanford et al. [3] reported early clinical experience demonstrating its efficacy against Pseudomonas infections, a dominant pathogen in burns at the time.
Agent selection
Silver-based agents
Monafo and West [4] provided a comprehensive review of topical burn therapy recommendations, confirming SSD as the most frequently used prophylactic agent due to its broad-spectrum activity, ease of application, patient tolerance, and low cost. They noted that mafenide acetate cream possesses superior eschar-penetrating characteristics, making it the agent of choice for early treatment of burn wound sepsis, though its use must be limited in duration and area due to systemic toxicity from carbonic anhydrase inhibition.
Depth-stratified approach
Greenhalgh [5] articulated a rational framework for selecting topical agents based on burn depth: superficial burns should be managed with agents that optimize re-epithelialization, while deep burns require antimicrobials that minimize microbial proliferation until definitive wound closure. This depth-stratified approach remains the standard conceptual model for topical agent selection.
Alternative agents
Fox et al. [8] explored zinc sulfadiazine as an alternative to SSD, demonstrating comparable clinical effectiveness with potentially fewer S. aureus colonies in a rat model. Although zinc sulfadiazine did not replace SSD in widespread clinical practice, this work highlighted ongoing efforts to address staphylococcal colonization that SSD manages less effectively.
Miller et al. [13] evaluated chlorhexidine phosphanilate (CHP) as a potential new topical agent, finding a dose-dependent relationship with patient-reported pain. While lower concentrations approached SSD in tolerability, pharmaceutical refinement was needed, illustrating the ongoing challenge of balancing antimicrobial efficacy with patient comfort.
Efficacy against resistant organisms
The emergence of multidrug-resistant organisms (MDROs) in burn units has prompted re-evaluation of topical agent efficacy. Neely et al. [6] conducted a multicenter study testing 47 MDROs from four burn hospitals against 11 commonly used topical agents. Overall, 80% of MDROs remained susceptible to topical agents compared with 88% of non-MDROs (P < 0.05). However, zones of inhibition were significantly smaller for MDROs (P < 0.002), indicating decreased susceptibility. Neomycin showed the most dramatic difference, with only 26% of MDROs susceptible compared to 74% of non-MDROs (P < 0.01). Mafenide acetate, silver nitrate, and Dakin's solution retained the broadest activity against resistant organisms.
For methicillin-resistant Staphylococcus aureus (MRSA) infections, Strock et al. [7] evaluated topical mupirocin (Bactroban) and found 100% in vitro activity against gram-positive isolates, including 51 predominantly MRSA strains. Quantitative wound biopsies in 13 patients with MRSA burn wound infections confirmed clinical efficacy predicted by the agar well diffusion assay in 92.3% of cases (P < 0.0005). Mupirocin's activity against gram-negative organisms was limited compared to mafenide acetate and SSD.
Antifungal agents
Fungal burn wound infections represent a particularly challenging subset. Barret et al. [9] reported a novel treatment for angioinvasive fungal infections using nystatin powder at 6,000,000 units/g, demonstrating successful eradication of massive angioinvasive fungal infections in four consecutively treated severely burned patients without adverse effects on wound healing.
Role in comprehensive wound management
Pruitt et al. [10] provided the most comprehensive review of burn wound infection pathophysiology and the role of topical agents in prevention. They established that the combination of effective topical antimicrobial chemotherapy and early burn wound excision has significantly reduced the overall incidence of invasive burn wound infections, while emphasizing that histologic examination of wound biopsies remains the only reliable method for distinguishing colonization from invasive infection.
For facial burns specifically, Leon-Villapalos et al. [11] reviewed topical management options, expanding the concept of topical therapy to include both acute and rehabilitation phases. The unique anatomy and functional importance of the face require tailored agent selection that balances antimicrobial coverage with preservation of re-epithelialization potential.
Rafla and Tredget [12] reviewed infection control in the burn unit, emphasizing that the type and quantity of microorganisms colonizing the wound influence future risk of invasive infection, reinforcing the importance of effective topical prophylaxis as a component of comprehensive infection prevention.
Rojas et al. [14] placed topical antimicrobial therapy within the broader pharmacotherapy landscape for burns, noting that advances in excision, grafting, and nutritional support work synergistically with topical agents to reduce morbidity and mortality.
Controversies and Evidence Gaps
The choice between silver sulfadiazine and newer silver-containing dressings (nanocrystalline silver, silver-impregnated foams) remains unresolved. While SSD is inexpensive and familiar, it requires frequent dressing changes and may delay epithelialization of superficial wounds. Newer dressings reduce change frequency but at substantially higher cost, and head-to-head comparative trials of adequate power are lacking.
Mafenide acetate cream remains the only topical agent with reliable eschar penetration, but its use is limited by pain on application and metabolic acidosis from carbonic anhydrase inhibition. Optimal dosing duration and the threshold for switching agents are not well defined.
The rising prevalence of MDROs in burn units challenges assumptions about topical efficacy. Although most topicals retain activity, the narrowing zones of inhibition suggest erosion of susceptibility over time. Whether topical agent rotation strategies can slow resistance development, as Neely et al. [6] data imply, has not been tested in clinical trials.
Honey-based products have emerging evidence in wound care broadly but lack burn-specific trials of sufficient quality to support routine use. The role of newer antiseptics such as polyhexamethylene biguanide (PHMB) in burn wound management also requires further study.
References
[1] Moyer CA et al. (1965). Treatment of large human burns with 0.5 per cent silver nitrate solution. PMID: 14333527 [2] Brentano L et al. (1966). Bacteriology of large human burns treated with silver nitrate. PMID: 5330066 [3] Stanford W et al. (1969). Clinical experience with silver sulfadiazine, a new topical agent for control of pseudomonas infections in burns. PMID: 5771755 [4] Monafo WW et al. (1990). Current treatment recommendations for topical burn therapy. PMID: 2226220 [5] Greenhalgh DG (2009). Topical antimicrobial agents for burn wounds. PMID: 19793554 [6] Neely AN et al. (2009). Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? PMID: 19060725 [7] Strock LL et al. (1990). Topical Bactroban (mupirocin): efficacy in treating burn wounds infected with methicillin-resistant staphylococci. PMID: 2123203 [8] Fox CL et al. (1990). Comparative evaluation of zinc sulfadiazine and silver sulfadiazine in burn wound infection. PMID: 2335547 [9] Barret JP et al. (1999). Topical nystatin powder in severe burns: a new treatment for angioinvasive fungal infections refractory to other topical and systemic agents. PMID: 10498358 [10] Pruitt BA et al. (1998). Burn wound infections: current status. PMID: 9451928 [11] Leon-Villapalos J et al. (2008). Topical management of facial burns. PMID: 18538480 [12] Rafla K et al. (2011). Infection control in the burn unit. PMID: 20561750 [13] Miller LM et al. (1990). Patient tolerance study of topical chlorhexidine diphosphanilate: a new topical agent for burns. PMID: 2383364 [14] Rojas Y et al. (2012). Burns: an update on current pharmacotherapy. PMID: 23121414